Expression of HIF-1α is related to a poor prognosis and tamoxifen resistance in contralateral breast cancer

Abstract

The increased percentage of HIF-1α-positive tumors formed during adjuvant tamoxifen suggests a role for HIF-1α in escaping tamoxifen's restraining effects on breast cancer. Implicating a potential benefit of HIF-inhibitors in targeting breast cancers resistant to endocrine therapy.